Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

被引：3237

作者：

Topalian, Suzanne L. ^{[1
]}

Drake, Charles G. ^{[2
,3
]}

Pardoll, Drew M. ^{[3
]}

机构：

[1] Sidney Kimmel Comprehens Canc Ctr, Dept Surg, Baltimore, MD 21287 USA

[2] Sidney Kimmel Comprehens Canc Ctr, Brady Urol Inst, Baltimore, MD 21287 USA

[3] Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21287 USA

来源：

CANCER CELL | 2015年 / 27卷 / 04期

关键词：

T-CELL-ACTIVATION; RESISTANT PROSTATE-CANCER; DOUBLE-BLIND; COSTIMULATORY MOLECULE; ANTI-PD-L1; ANTIBODY; ANTITUMOR IMMUNITY; EFFECTOR FUNCTION; CLINICAL ACTIVITY; PD-1; BLOCKADE; B7; FAMILY;

D O I：

10.1016/j.ccell.2015.03.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The immune system recognizes and is poised to eliminate cancer but is held in check by inhibitory receptors and ligands. These immune checkpoint pathways, which normally maintain self-tolerance and limit collateral tissue damage during anti-microbial immune responses, can be co-opted by cancer to evade immune destruction. Drugs interrupting immune checkpoints, such as anti-CTLA-4, anti-PD-1, anti-PD-L1, and others in early development, can unleash anti-tumor immunity and mediate durable cancer regressions. The complex biology of immune checkpoint pathways still contains many mysteries, and the full activity spectrum of checkpoint-blocking drugs, used alone or in combination, is currently the subject of intense study.

引用

页码：450 / 461

页数：12

共 114 条

[1] Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired [J].

Ahmadzadeh, Mojgan ;

Johnson, Laura A. ;

Heemskerk, Bianca ;

Wunderlich, John R. ;

Dudley, Mark E. ;

White, Donald E. ;

Rosenberg, Steven A. .

BLOOD, 2009, 114 (08) :1537-1544

[2] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[3] Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization [J].

Baitsch, Lukas ;

Legat, Amandine ;

Barba, Leticia ;

Marraco, Silvia A. Fuertes ;

Rivals, Jean-Paul ;

Baumgaertner, Petra ;

Christiansen-Jucht, Celine ;

Bouzourene, Hanifa ;

Rimoldi, Donata ;

Pircher, Hanspeter ;

Rufer, Nathalie ;

Matter, Maurice ;

Michielin, Olivier ;

Speiser, Daniel E. .

PLOS ONE, 2012, 7 (02)

[4] Restoring function in exhausted CD8 T cells during chronic viral infection [J].

Barber, DL ;

Wherry, EJ ;

Masopust, D ;

Zhu, BG ;

Allison, JP ;

Sharpe, AH ;

Freeman, GJ ;

Ahmed, R .

NATURE, 2006, 439 (7077) :682-687

[5] Killer Immunoglobulin-like Receptors and Tumor Immunity [J].

Benson, Don M., Jr. ;

Caligiuri, Michael A. .

CANCER IMMUNOLOGY RESEARCH, 2014, 2 (02) :99-104

[6] Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection [J].

Blackburn, Shawn D. ;

Shin, Haina ;

Haining, W. Nicholas ;

Zou, Tao ;

Workman, Creg J. ;

Polley, Antonio ;

Betts, Michael R. ;

Freeman, Gordon J. ;

Vignali, Dario A. A. ;

Wherry, E. John .

NATURE IMMUNOLOGY, 2009, 10 (01) :29-37

[7] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[8] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[9] Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses [J].

Butte, Manish J. ;

Keir, Mary E. ;

Phamduy, Theresa B. ;

Sharpe, Arlene H. ;

Freeman, Gordon J. .

IMMUNITY, 2007, 27 (01) :111-122

[10]

Chambers CA, 1998, EUR J IMMUNOL, V28, P3137, DOI 10.1002/(SICI)1521-4141(199810)28:10<3137::AID-IMMU3137>3.3.CO

← 1 2 3 4 5 6 7 8 9 10 →